News

September 20, 2017

Waist and Widespread Fat Contribute to Distinct Breast Cancer Subtypes, Study Finds

While both widespread (subcutaneous) and abdominal (visceral) fat accumulation contribute to breast cancer, the two types of obesity are linked to different subtypes of the disease, a new study from China ... Read more

September 18, 2017September 18, 2017

MasSpec Pen Accurately Detects Cancer Cells During Surgery in Seconds

News

Researchers at the University of Texas at Austin developed an automated handheld device that accurately identifies cancerous tissue in as little as 10 seconds. The device, called MasSpec Pen, is ... Read more

September 15, 2017September 15, 2017

Endomag Receives CE Mark Approval for Minimally Invasive Breast Cancer Surgery Marker

News

Medical device developer Endomag has recently received CE Mark approval for Magseed, its minimally invasive breast marker used to guide surgeons during breast cancer surgery. Magseed will be distributed in Europe ... Read more

September 13, 2017

Abemaciclib Combo Therapy Improves Outcome in Certain Advanced Breast Cancer Patients

News

Adding abemaciclib to endocrine therapy can reduce the risk of breast cancer progressing in newly diagnosed postmenopausal women, according to interim results of a Phase 3 clinical trial. Italian researcher Angelo Di ... Read more

September 8, 2017September 8, 2017

LUM Imaging System to Detect Residual Cancer During Surgery to Start Advanced Clinical Trial

News

A possibly pivotal clinical trial using an imaging technology – the LUM Imaging System by Lumicell — to detect residual tumor tissue in breast cancer patients undergoing surgery is in the ... Read more

September 7, 2017

Even Small Breast Tumors Can be Aggressive, and Patients Can Benefit from Chemotherapy, Study Shows

News

While many doctors consider small tumors less harmful, new data from the international MINDACT breast cancer study suggests otherwise. In the study, nearly one in four early-stage breast cancer patients ... Read more

September 5, 2017September 5, 2017

FDA Approves Faslodex As First-Line Therapy for HR+, HER2– Advanced Breast Cancer

News

The U.S. Food and Drug Administration has approved Faslodex (fulvestrant) as a first-line treatment for patients with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, ... Read more

July 18, 2017

Nerlynx Approved by FDA for HER2-positive Breast Cancer Patients to Reduce Risk of Recurrence

News

The U.S. Food and Drug Administration (FDA) approved Puma Biotechnology‘s Nerlynx (neratinib) as an extended adjuvant treatment of early-stage, HER2-positive breast cancer. This means that Nerlynx is the first extended adjuvant therapy ... Read more

June 9, 2017September 20, 2017

Keytruda Helped Patients with Metastatic Triple-Negative Breast Cancer, Studies Find

News

Keytruda (pembrolizumab) was effective in treating triple-negative breast cancer regardless of whether women had received previous treatment, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) ... Read more

June 8, 2017

Response to Neratinib and Xeloda Combo Seen in Breast Cancer Patients with Brain Metastasis

News

Combining Puma Biotechnology’s candidate therapy PB272, also known as neratinib, with the chemotherapy drug Xeloda (capecitabine) appears to have therapeutic potential for patients with advanced HER2-positive breast cancer and brain metastasis, who were not previously treated ... Read more